gemcitabine has been researched along with pf 3084014 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Korangath, P; Maitra, A; Pai, SG; Rajeshkumar, NV; Rasheed, ZA; Streppel, MM; Yabuuchi, S | 1 |
2 other study(ies) available for gemcitabine and pf 3084014
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Tumor Cells, Cultured; Valine; Xenograft Model Antitumor Assays | 2013 |